Company intelligence / Profile preview
Adicet Bio
Redwood City, California, United Statesadicetbio.com ↗
- Ownership
- Public · ACET
- Development stage
- Other
01
Overview
Currently conducting Phase 1 trials for ADI-001 in autoimmune diseases with preliminary data in lupus nephritis expected in 1H 2025. Also conducting Phase 1 trial for ADI-270 in metastatic/advanced clear cell renal cell carcinoma with preliminary data expected in 1H 2025.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Allogeneic gamma delta T cell therapiesCAR T cell therapies
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
Strategic collaboration with Regeneron Pharmaceuticals, Inc. (established in August 2016)
04
Financials
- Market cap
- $27.3M
- Total revenue
- $0
- Enterprise value
- $-61.5M
Beyond the preview
Go deeper on Adicet Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adicet Bio.